Back to Journals » Vascular Health and Risk Management » Volume 13

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy

Authors Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A, Di Biase M, Brunetti ND

Received 22 June 2016

Accepted for publication 27 October 2016

Published 16 February 2017 Volume 2017:13 Pages 29—41

DOI https://doi.org/10.2147/VHRM.S95044

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Professor Daniel Duprez


Nicola Tarantino,1 Francesco Santoro,1,2 Luisa De Gennaro,3 Michele Correale,1 Francesca Guastafierro,1 Antonio Gaglione,1 Matteo Di Biase,1 Natale Daniele Brunetti1

1University of Foggia, Foggia, Italy; 2Asklepios Klinik – St Georg, Hamburg, Germany; 3Ospedale San Paolo, Bari, Italy

Abstract: Lipids disorder is the principal cause of atherosclerosis and may present with several forms, according to blood lipoprotein prevalence. One of the most common forms is combined dyslipidemia, characterized by high levels of triglycerides and low level of high-density lipoprotein. Single lipid-lowering drugs may have very selective effect on lipoproteins; hence, the need to use multiple therapy against dyslipidemia. However, the risk of toxicity is a concerning issue. In this review, the effect and safety of an approved combination therapy with simvastatin plus fenofibrate are described, with an analysis of pros and cons resulting from randomized multicenter trials, meta-analyses, animal models, and case reports as well.

Keywords: fibrates, simvastatin, fixed-dose combination, combined dyslipidemia, review

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]